Mark Holland

Mark Holland got pharmacare over the line — at least the first phase of it. Diabetes medications and contraception covered under a universal first-dollar program is real and reaches millions of Canadians who had to choose between prescriptions and groceries. Yes, it's narrower than advocates wanted and slower than it should have been. But after decades of pharmacare being a promise that evaporated after every election, having legislation on the books matters. The healthcare system more broadly remains under provincial delivery constraints that a federal Health Minister can't directly fix. Holland has been honest about where the federal role begins and ends — that honesty is frustrating when the system is failing people but it's more useful than pretending Ottawa can fix what provinces deliver.

Mark Holland serves as Canada's Minister of Health and has been the face of the federal government's pharmacare push — one of the longest-standing undelivered promises in Liberal political history, dating back to the 1997 Romanow Commission recommendations and deployed as a campaign commitment across multiple election cycles before partial legislation finally moved forward. The Canada Pharmacare Act that passed under Holland's tenure represents genuine progress: a first-dollar coverage framework for diabetes medications and contraceptives, with a commitment to expand coverage categories over time. Critics on the left argue it is too narrow and too slow; critics on the right argue that pharmacare is a provincial jurisdiction and the federal government is encroaching. Holland has had to manage both sets of criticism while also negotiating the practical politics of a minority Parliament. His work on healthcare system capacity — working with provinces on the workforce crisis, the emergency department backlogs, and the surgical wait times that have defined the post-COVID healthcare experience for Canadians — has been more constrained by the structural federal-provincial division of responsibility. Health is delivered by provinces; the federal government funds it through transfers. The leverage available to a federal Health Minister to improve delivery is primarily financial rather than operational. Holland is energetic, accessible, and genuinely committed to the pharmacare file as a policy outcome rather than just a talking point. The gap between the ambition of universal pharmacare and what has actually been delivered reflects the political constraints of minority government more than the commitment of the minister.